These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 6374338)
1. Antitumor anthracyclines: recent developments. Arcamone F Med Res Rev; 1984; 4(2):153-88. PubMed ID: 6374338 [No Abstract] [Full Text] [Related]
2. A new antitumor antibiotic, carminomycin (NSC-180024). Gause GF; Brazhnikova MG; Shorin VA Cancer Chemother Rep; 1974; 58(2):255-6. PubMed ID: 4830498 [No Abstract] [Full Text] [Related]
3. Modes of resistance to anthracyclines and other natural products. Kessel D; Romine M; Decker D Prog Clin Biol Res; 1986; 223():81-93. PubMed ID: 3543948 [No Abstract] [Full Text] [Related]
5. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin. Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823 [No Abstract] [Full Text] [Related]
6. Anthracycline antibiotic pharmacology and metabolism. Bachur NR Cancer Treat Rep; 1979 May; 63(5):817-20. PubMed ID: 455323 [TBL] [Abstract][Full Text] [Related]
7. The structure of SN-07 chromophore. Kimura K; Nakayama S; Miyata N; Takeshita Y; Kawanishi G J Antibiot (Tokyo); 1988 Mar; 41(3):411-4. PubMed ID: 3366698 [No Abstract] [Full Text] [Related]
8. A chemical perspective on the anthracycline antitumor antibiotics. Abdella BR; Fisher J Environ Health Perspect; 1985 Dec; 64():4-18. PubMed ID: 3913602 [TBL] [Abstract][Full Text] [Related]
9. Biologic properties of three anthracyclines as a function of lipophilicity. Kessel D Biochem Pharmacol; 1979 Oct; 28(19):3028-30. PubMed ID: 518699 [No Abstract] [Full Text] [Related]
10. Structural studies on rhodilunancins A and B. Li M; Chen YL J Antibiot (Tokyo); 1986 Mar; 39(3):430-6. PubMed ID: 3700244 [TBL] [Abstract][Full Text] [Related]
11. New anthracycline antibiotics, auramycins and sulfurmycins. I. Isolation and characterization of auramycins A and B, and sulfurmycins A and B. Fujiwara A; Hoshino T; Tazoe M; Fujiwara M J Antibiot (Tokyo); 1982 Feb; 35(2):164-75. PubMed ID: 6951825 [No Abstract] [Full Text] [Related]
12. Facile exchange of the cyano group in highly potent anticancer cyanomorpholinyl anthracyclines. Peters JH; Gordon GR; Nolen HW; Tracy M; Thomas DW Biochem Pharmacol; 1988 Jan; 37(2):357-61. PubMed ID: 3422560 [No Abstract] [Full Text] [Related]
13. Redox activities of antitumor anthracyclines determined by microsomal oxygen consumption and assays for superoxide anion and hydroxyl radical generation. Peters JH; Gordon GR; Kashiwase D; Lown JW; Yen SF; Plambeck JA Biochem Pharmacol; 1986 Apr; 35(8):1309-23. PubMed ID: 3008758 [TBL] [Abstract][Full Text] [Related]
14. The antitumor effects of anthracyclines. The importance of the carbomethoxy-group at position-10 of marcellomycin and rudolfomycin. DuVernay VH; Essery JM; Doyle TW; Bradner WT; Crooke ST Mol Pharmacol; 1979 Mar; 15(2):341-56. PubMed ID: 470932 [No Abstract] [Full Text] [Related]
18. Biochemical mechanism for resistance to anthracycline antibiotics. Inaba M Prog Clin Biol Res; 1986; 223():35-44. PubMed ID: 3468518 [No Abstract] [Full Text] [Related]
19. Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents. Schwartz HS; Kanter PM Cancer Treat Rep; 1979 May; 63(5):821-5. PubMed ID: 287555 [TBL] [Abstract][Full Text] [Related]
20. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Young CW; Raymond V Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251 [No Abstract] [Full Text] [Related] [Next] [New Search]